Echosens and Boehringer Ingelheim Expand Partnership for MASH Diagnosis

Echosens and Boehringer Ingelheim have announced an expansion of their long-standing partnership to advance the diagnosis and care of metabolic dysfunction-associated steatohepatitis (MASH), announced in a press release. This collaboration aims to address the urgent need for early screening and diagnosis of MASH, a chronic liver disease affecting over 250 million people worldwide.

The partnership will focus on raising awareness among patients, healthcare professionals, and policymakers about the importance of early detection. It will also promote the adoption of streamlined care pathways and expand access to non-invasive technologies (NITs) for MASH diagnosis. Echosens' FibroScan®, a non-invasive liver assessment technology, will continue to play a crucial role in Boehringer Ingelheim's ongoing research and clinical trials.

By combining their diagnostic and therapeutic expertise, the two companies aim to close gaps in awareness and clinical adoption, ultimately improving liver health outcomes globally.